Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study

Multiple Sclerosis

Volumn 14, Issue 9, 2008, Pages 1242-1249

  Brochet, Bruno ^a,c   Deloire, M S A ^a   Bonnet, M ^a   Salort Campana, E ^b   Ouallet, J C ^a   Petry, K G ^a   Dousset, V ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^c Affections de la Myeline EA 2966   (France)

Author keywords

Cognition; EDSS; MSFC; Multiple sclerosis; PASAT; SDMT

Indexed keywords

ADULT; ARTICLE; CLINICAL EVALUATION; COGNITION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; NUCLEAR MAGNETIC RESONANCE IMAGING; PACED AUDITORY SERIAL ADDITION TEST; SCORING SYSTEM; SYMBOL DIGIT MODALITY TEST; COGNITIVE DEFECT; DISABILITY; DISEASE COURSE; FOLLOW UP; HOSPITALIZATION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING;

ADULT; COGNITION DISORDERS; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX;

EID: 59249103808     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508094398     Document Type: Article

References (60)

1. Hoffmann S, Tittgemeyer M, von Cramon DY. Cognitive impairment in multiple sclerosis. Curr Opin Neurol 2007; 20: 275-280.
2. Pelosi L, Geesken JM, Holly M, Hayward M, Blumhardt LD. Working memory impairment in early multiple sclerosis. Evidence from an event-related potential study of patients with clinically isolated myelopathy. Brain 1997; 120: 2039-2058.
3. Ranjeva JP, Audoin B, Au Duong MV. Structural and functional surrogates of cognitive impairment at the very early stage of multiple sclerosis. J Neurol Sci 2006; 245: 161-167.
4. Feinstein A, Kartsounis LD, Miller DH, Youl BD, Ron MA. Clinically isolated lesions of the type seen in multiple sclerosis: A cognitive, psychiatric, and MRI follow up study. J Neurol Neurosurg Psychiatry 1992; 55: 869-876.
5. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: Frequency, patterns & prediction. Neurology 1991; 41: 685-691.
6. Benedict RH, Cookfair D, Gavett R. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 2006; 12: 549-558.
7. Deloire MSA, Salort E, Bonnet M. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76: 519-526.
8. Nocentini U, Pasqualetti P, Bonavita S. Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Mult Scler 2006; 12: 77-87.
9. Huijbregts SC, Kalkers NF, De Sonneville LM, De Groot V, Reuling IE, Polman CH. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive, MS. Neurology 2004; 63: 335-339.
10. Denney DR, Sworowski LA, Lynch SG. Cognitive impairment in three subtypes of multiple sclerosis. Arch Clin Neuropsychol 2005; 20: 967-981.
11. Zakzanis K. Distinct neurocognitive profiles in multiple sclerosis subtypes. Arch Clin Neuropsychol 2000; 15: 115-136.
12. Bobholz JA, Rao SM. Cognitive dysfunction in multiple sclerosis: A review of recent developments. Curr Opin Neurol 2003; 16: 283-288.
13. Brochet B, Bonnet M, Deloire M, Hamel D, Salort-Campana E. Cognitive disorders in multiple sclerosis. Rev Neurol (Paris) 2007; 163: 697-702.
14. Amato MP, Ponziani G, Siracusa G, Sorbi S,. Cognitive dysfunction in early-onset multiple sclerosis: A reappraisal after 10 years. Arch Neurol 2001; 58: 1602-1606.
15. Piras MR, Magnano I, Canu ED. Longitudinal study of cognitive dysfunction in multiple sclerosis: Neuropsychological, neuroradiological, and neurophysiological findings. J Neurol Neurosurg Psychiatry 2003; 74: 878-885.
16. Bergendal G, Fredrikson S, Almkvist O. Selective decline in information processing in subgroups of multiple sclerosis: An 8-year longitudinal study. Eur Neurol 2007; 57: 193-202.
17. Schwid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP.; for the Copaxone Study Group. Cognitive function in relapsing multiple sclerosis: Minimal changes in a 10-year clinical trial. J Neurol Sci 2007; 255: 57-63.
18. Rovaris M, Comi G, Filippi M,. MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction. J Neurol Sci 2006; 245: 111-116.
19. Benedict RH, Bruce JM, Dwyer MG. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 2006; 63: 1301-1306.
20. Christodoulou C, Krupp LB, Liang Z. Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. Neurology 2003; 60: 1793-1798.
21. Houtchens MK, Benedict RH, Killiany R. Thalamic atrophy and cognition in multiple sclerosis. Neurology 2007; 69: 1213-1223.
22. Zivadinov R, Sepcic J, Nasuelli D. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70: 773-780.
23. Lazeron RH, Boringa JB, Schouten M. Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. Mult Scler 2005; 11: 524-531.
24. Hildebrandt H, Hahn HK, Kraus JA, Schulte-Herbruggen A, Schwarze B, Schwendemann G. Memory performance in multiple sclerosis patients correlates with central brain atrophy. Mult Scler 2006; 12: 428-436.
25. Tekok-Kilic A, Benedict RH, Weinstock-Guttman B. Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. Neuroimage 2007; 36: 1294-1300.
26. Rovaris M, Filippi M, Falautano M. Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology 1998; 50: 1601-1608.
27. Filippi M, Tortorella C, Rovaris M. Changes in the normal-appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68: 157-161.
28. Cox D, Pelletier D, Genain C. The unique impact of changes in normal appearing brain tissue on cognitive dysfunction in secondary progressive multiple sclerosis patients. Mult Scler 2004; 10: 626-629.
29. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
30. Hobart J, Freeman J, Thompson A. Kurtzke scales revisited: The application of psychometric methods to clinical intuition. Brain 2000; 123: 1027-1040.
31. Rudick R, Antel J, Confavreux C. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997; 42: 379-382.
32. Cutter GR, Baier ML, Rudick RA. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-882.
33. Hoogervorst EL, Kalkers NF, Uitdehaag BM, Polman CH. A study validating changes in the multiple sclerosis functional composite. Arch Neurol 2002; 59: 113-116.
34. Gronwall DM. Paced auditory serial-addition task: A measure of recovery from concussion. Percept Mot Skills 1977; 44: 367-373.
35. Tombaugh TN. A comprehensive review of the Paced Auditory Serial Addition Test (PASAT). Arch Clin Neuropsychol 2006; 21: 53-76.
36. Chronicle EP, MacGregor NA. Are PASAT scores related to mathematical ability. Neuropsychol Rehabil 1998; 8: 273-282.
37. Hiscock M, Caroselli JS, Kimball LE. Paced serial addition: modality-specific and arithmetic-specific factors. J Clin Exp Neuropsychol 1998; 20: 463-472.
38. Camp SJ, Stevenson VL, Thompson AJ. Cognitive function in primary progressive and transitional progressive multiple sclerosis: A controlled study with MRI correlates. Brain 1999; 122: 1341-1348.
39. Smith A. Symbol digits modalities test. Los Angeles: Western psychological Services; 1982.
40. Deloire MS, Bonnet MC, Salort E. How to detect cognitive dysfunction at early stages of MS. Mult Scler 2006; 12: 445-452.
41. Parmenter BA, Weinstock-Guttman B, Garg N, Munschauer F, Benedict RH. Screening for cognitive impairment in multiple sclerosis using the symbol digit modalities test. Mult Scler 2007; 13: 52-57.
42. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): An integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999; 5: 244-250.
43. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53: 1698-1704.
44. Kalkers NF, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F. Brain atrophy in multiple sclerosis: Impact of lesions and of damage of whole brain tissue. Mult Scler 2002; 8: 410-414.
45. de consensus sur la sclérose en plaques, Paris, 7 et 8 juin 2001, Organisée par la Fédération Française de Neurologie avec la participation de l'ANAES Recommandations du Jury. Rev Neurol (Paris) 2001; 157: 1184-1192.
46. Freedman MS, Blumhardt LD, Brochet B. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler 2002; 8: 19-23.
47. Cohen JA, Cutter GR, Fischer JS. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-687.
48. Sepulcre J, Vanotti S, Hernandez R. Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test. Mult Scler 2006; 12: 187-195.
49. Levine AJ, Miller EN, Becker JT, Selnes OA, Cohen BA. Normative data for determining significance of test-retest differences on eight common neuropsychological instruments. Clin Neuropsychol 2004; 18: 373-384.
50. Benedict RH. Effects of using same-versus alternate-form memory tests during short-interval repeated assessments in multiple sclerosis. J Int Neuropsychol Soc 2005; 11: 727-736.
51. Amato MP, Ponziani G, Pracucci G, Bracco L, Siracusa G, Amaducci L,. Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol 1995; 52: 168-172.
52. Hohol MJ, Guttmann CR, Orav J. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol 1997; 54: 1018-1025.
53. Patti F, Failla G, Ciancio MR, L'Episcopo MR, Reggio A. Neuropsychological, neuroradiological and clinical findings in multiple sclerosis. A 3 year follow-up study. Eur J Neurol 1998; 5: 283-286.
54. Sperling RA, Guttmann CR, Hohol MJ. Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: A longitudinal study. Arch Neurol 2001; 58: 115-121.
55. Camp SJ, Stevenson VL, Thompson AJ. A longitudinal study of cognition in primary progressive multiple sclerosis. Brain 2005; 128: 2891-2898.
56. Henry JD, Beatty WW. Verbal fluency deficits in multiple sclerosis. Neuropsychologia 2006; 44: 1166-1174.
57. Solari A, Radice D, Manneschi L, Motti L, Montanari E. The multiple sclerosis functional composite: Different practice effects in the three test components. J Neurol Sci 2005; 228: 71-74.
58. Rudick RA, Cutter G, Reingold S. The multiple sclerosis functional composite: A new clinical outcome measure for multiple sclerosis trials. Mult Scler 2002; 8: 359-365.
59. Rudick RA, Cutter G, Baier M. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 2001; 56: 1324-1330.
60. Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C, Thompson A. Outcome measures for multiple sclerosis clinical trials: Relative measurement precision of the Expanded Disability Status scale and Multiple Sclerosis Functional Composite. Mult Scler 2004; 10: 41-46.